HC Wainwright Expects Lower Earnings for Caribou Biosciences

Key Points

• Analysts at HC Wainwright have revised their Q3 2025 earnings estimates for Caribou Biosciences down to ($0.36) per share, indicating a decrease from the previous forecast of ($0.33).
• Caribou Biosciences' stock has been upgraded from a "sell" to a "hold" rating by Wall Street Zen, with an average consensus rating of "Buy" and a target price of $6.67.
• As of recent trading, Caribou Biosciences' shares are priced at $2.13, reflecting a considerable 14.5% increase in value.

Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) - Investment analysts at HC Wainwright lowered their Q3 2025 earnings estimates for shares of Caribou Biosciences in a note issued to investors on Tuesday, September 23rd. HC Wainwright analyst R. Burns now forecasts that the company will post earnings per share of ($0.36) for the quarter, down from their previous estimate of ($0.33). The consensus estimate for Caribou Biosciences' current full-year earnings is ($1.64) per share. HC Wainwright also issued estimates for Caribou Biosciences' Q4 2025 earnings at ($0.37) EPS and FY2025 earnings at ($1.51) EPS.

Separately, Wall Street Zen raised Caribou Biosciences from a "sell" rating to a "hold" rating in a report on Sunday, August 24th. Three research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $6.67.

Caribou Biosciences Stock Up 14.5%

Shares of NASDAQ:CRBU opened at $2.13 on Thursday. The company has a market cap of $198.35 million, a P/E ratio of -1.20 and a beta of 2.54. Caribou Biosciences has a 52 week low of $0.66 and a 52 week high of $3.00. The company has a 50-day moving average price of $1.94 and a 200 day moving average price of $1.36.

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last released its earnings results on Tuesday, August 12th. The company reported ($0.35) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.05. Caribou Biosciences had a negative net margin of 1,800.93% and a negative return on equity of 62.35%. The company had revenue of $2.67 million during the quarter, compared to analysts' expectations of $1.64 million.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in CRBU. Cambridge Investment Research Advisors Inc. acquired a new position in shares of Caribou Biosciences during the 1st quarter worth approximately $559,000. Aberdeen Group plc raised its holdings in shares of Caribou Biosciences by 118.3% in the second quarter. Aberdeen Group plc now owns 897,579 shares of the company's stock worth $1,131,000 after acquiring an additional 486,435 shares during the last quarter. AQR Capital Management LLC raised its holdings in shares of Caribou Biosciences by 741.6% in the first quarter. AQR Capital Management LLC now owns 525,878 shares of the company's stock worth $480,000 after acquiring an additional 463,391 shares during the last quarter. Two Sigma Advisers LP raised its holdings in shares of Caribou Biosciences by 39.5% in the fourth quarter. Two Sigma Advisers LP now owns 1,470,700 shares of the company's stock worth $2,338,000 after acquiring an additional 416,600 shares during the last quarter. Finally, Ameriprise Financial Inc. acquired a new position in shares of Caribou Biosciences in the fourth quarter worth $649,000. Institutional investors and hedge funds own 77.51% of the company's stock.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.